

# TABLE OF CONTENTS

May 4 & 11, 2009

No. 2138

## BUSINESS

- 1 Sanofi-aventis Aims at No. 5 Place in Japan in 5 Years: Dr Chocat
  - Apidra to Reach Market within 2009
  - Apidra Approved as Rapid-Acting Insulin Analogue
  - Sanofi-aventis Acquires Medley of Brazil
- 3 Shionogi to Develop In-house Products by Sugar Chain Analysis, Molecular Imaging
  - Confident about Developing 5 Compounds up to PII
- 4 Kyowa Kirin Aiming at Becoming Global Specialty Pharma
  - POTELLIGENT Technology Used for 8 of 10 Preclinical Compounds
- 5 GSK to Lead Respiratory Drug Market with Adair
- 5 Toyota Tsusho to Represent ChemRoutes in Japan
- 6 Market for Drugs for Hyperlipidemia to Exceed ¥400 Bil. in 2013: Fuji-Keizai Data Book
- 6 **BUSINESS NEWS IN BRIEF**
  - GSK, Nippon Kayaku Start Copromotion of Tykerb
  - GSK, Pfizer Create a New HIV Specialist Company
  - GSK to Acquire Stiefel
  - Tsumura to Create Crude Drug Production Center in Yubari
  - Quintiles Reaches 400th Trial Using EDC

## TOPICS

- 5 Shionogi Expands Support Systems for Female MRs
- 11 Working Hours of Obstetricians Longest in Japan
- 23 Astellas Provides Support for Children's Daycare Fees
- 23 Novartis Introduces Telework Program Permitting Work at Home

## REGULATORY

- 8 PhRMA Will Support NHI Price Maintenance System: Mr Sekiguchi
- 8 *Koroshō* to Speed Up Development of Anticancer, Pediatric Drugs Using Supplementary Budget
- 9 More Companies Show Interest in Collaborative Multinational Trials: Mr Nakagaki
- 9 NBI's Telmisartan + HCT Combinations Approved
- 10 **REGULATORY NEWS IN BRIEF**
  - Eli Lilly's AD/HD Agent Strattera Approved
  - GSK's Allermist Nasal Spray Approved for Allergic Rhinitis
  - Clozaril Approved for Treatment-Resistant Schizophrenia
  - Once-Daily Treatment at 500 mg Approved for Cravit

- Doxil Approved for Recurrent Ovarian Cancer
- Doxil Excluded from DPC Payment When Used for Ovarian Cancer Worsened after Chemotherapy
- Everolimus Granted Fast-Track Status: Novartis

## R&D

- 12 Takeda Deals with Soaring R&D Costs through 2 Strategies
- 12 Enhance Japan's Presence in Multinational Clinical Trials
- 13 NEDO to Start Large-Scale Clinical Trial on AD
- 13 Large-Scale Trial on Risk of Bone Fractures due to TZD Underway in Europe
- 14 Gov't to Earmark ¥79.0 Bil. to Promote Development of Unapproved Drugs
  - Council Calls For Encouragement of Development of 50 Unapproved Drugs
- 14 **R&D NEWS IN BRIEF**
  - Banyu Participates in Global Study on MK-0683
  - Takara Bio to Begin Gene Therapy for Leukemia
  - Takeda Drops TAK-379
  - Safety of SCH 530348 Confirmed in PII Study: Schering-Plough
  - Plavix + Aspirin Reduce Stroke More than Aspirin Alone
  - Significance of Reduction in hsCRP by Crestor Confirmed: JUPITER Study

## GENERIC

- 16 Pharmacists Should Be Encouraged to Dispense More Generics
- 17 JSHP to More Actively Cooperate with the Use of More Generics
- 17 Patient Education Important to Promote Use of Generics
- 18 **Commentary**
  - Clearer Criteria Needed for Patent Period Restoration

## SELF-MEDICATION

- 20 SSP Aims at ¥2 Bil. with Switch OTC Version of Diclofenac
- 20 Magnesium Oxide Should Remain Class 3 OTC Drug: Society
- 21 Taisho: Switch OTC Drug Containing Tiquizium Bromide

## OPINION

- 21 **OPINION**
  - Focusing on the Task at Hand: Philip Carrigan

## MEDICAL FACILITIES & NURSING CARE

- 22 Bonoteo Prevents Fractures in Severe Osteoporosis Patients
- 22 Explanation of Steroids Required to Overcome Patient's Anxieties